RegMed platform

Regenerative Medicine Innovation Platform - RegMed - Innovatieplatform voor Regeneratieve Geneeskunde. Dit is een innovatieproject ondersteund door kennisregio Vlaams-Brabant.
Cluster(s): health

RegMed:  Regenerative Medicine Innovation Platform

The province of Flemish Brabant (Belgium) and its neighbouring regions together have a leading role in regenerative and personalised medicine research, translation, industrialisation, dissemination and clinical implementation. Also a critical mass of experienced and complementary actors along the complete value chain is present in this region. To maintain and strengthen this unique and high potential position in regenerative medicine a customised strategic innovation platform was established.

The goal of this Regenerative Medicine Innovation Platform (RegMed) is to create a leading public-private community that, by building on its regional actors, can drive regenerative medicine towards a real industry with clinical applications and a socio-economical return.

Look for more information about the platform, the cross-border cooperations, the technolgy schowcases ... Click on the pictures on the right side.

Please contact for more information: Jan Schrooten, Antleron, jan.schrooten@antleron.com, tel +32 (0) 494 91 47 74



RegMed: Innovatieplatform voor Regeneratieve Geneeskunde

Aan de top
Vlaams-Brabant staat aan de top in Europa op het onderzoeksgebied van ‘regeneratieve geneeskunde’. Dat is een nieuwe tak van de geneeskunde waarbij artsen je weer gezond maken door bijvoorbeeld een nieuwe nier, huid of kraakbeen te bouwen uit gekweekte cellen en biomaterialen. Neen, dit is geen sciencefiction: wetenschappers, ingenieurs en artsen verwachten een aantal van die oplossingen al over enkele jaren toe te passen. Ze combineren daarvoor technieken zoals het kweken van biologisch en synthetisch materiaal in een bioreactor, met 3D-printing, waarbij je eender welk materiaal laag na laag op elkaar aanbrengt of print.

Stap voor stap
Deze nieuwe mogelijkheden zullen stap voor stap doorbreken.

  • De verwachting is dat over twee tot vijf jaar huid-, kraakbeen- en botvervangende implantaten klaar voor gebruik zijn.
  • Over vijf tot tien jaar zou weefsel- en orgaanmateriaal om hart en nieren te vervangen of herstellen op de markt komen.
  • En over twintig jaar kan het tekort aan transplantatieorganen opgelost raken, als het mogelijk wordt om ‘weefsels op bestelling’ te realiseren. Vooraleer deze nieuwe generatie implantaten klinisch beschikbaar zal zijn, kunnen ze als ‘labo-organen’ op kortere termijn meteen ook andere geneeskundige ontwikkelingen in een stroomversnelling brengen. Nieuwe medicijnen op labo-organen testen kan helpen om nog betere medicijnen te ontwikkelen, op maat van de patiënt.  

Samen sterk
Geen enkele universiteit, kliniek of bedrijf heeft alle kennis en kunde in huis om de noodzakelijke volgende stappen op eigen houtje te zetten. Met steun van de provincie hebben alle betrokken regionale spelers daarom een Innovatieplatform voor Regeneratieve Geneeskunde opgezet. Bedoeling van het platform is om met de meer dan twintig partners in overleg het pad uit te tekenen en gezamenlijk tot actie over te gaan. Op die manier blijft onze regio een voortrekker in dit innovatieve domein. Het platform zoekt ook internationale samenwerkingen met andere regio’s die inzetten op regeneratieve geneeskunde, zoals met Nederlands-Limburg.

Niet-genezende breuken

  • Enkele voortrekkers binnen het platform zijn de bedrijven Materialise en Layerwise, die via 3D-printing implantaten maakt.
  • Imec dat een lensvrije microscoop ontwikkelt die de opvolging en controle van celkweken beter en betaalbaarder maakt.
  • En de onderzoekers van het KU Leuven kennisplatform Prometheus die gespecialiseerd zijn in de celkweek en de combinatie met biomaterialen om beenderen op basis van eigen cellen te creëren. Zij werken inmiddels een scenario uit om een eerste implantaat uit levend materiaal te realiseren voor kinderen met niet-helende botbreuken.

Kijk voor meer info over het platform, de internationale samenwerking, de technologische onderzoekssamenwerkingen... Klik op de figuren in de rechterbalk

Meer info: Jan Schrooten, Antleron, jan.schrooten@antleron.com, tel +32 (0) 494 91 47 74

Partners en actoren van dit project

Bedrijven:

AML Clinical Services BVBA

RegMed platform

AML Clinical Services provides focused clinical research services to pharmaceutical, medical device and biotechnology companies, CROs and research sites.

We can advise and support members of the Reg Med platform in the start-up and monitoring of  their clinical trials. We also provide training in the regulatory aspects of clinical trials.

Contact: Anne-Mie Lenaers

Antleron bvba

RegMed platform

Antleron, an engineering start-up, aims to accelerate the development of next generation advanced therapies and medical devices by merging the potential of cells, biomaterials, biologics, 3D printing and bioreactors. Being part of the RegMed community is essential for Antleron’s business philosophy as it wants to run a project-based collaborative development model at the interface between life science and manufacturing industry to deliver socio-economically viable regenerative products that address unmet clinical needs.

Contact: jan.schrooten@antleron.com

CMAST

RegMed platform
  • Managing multi-stakeholder projects is our passion and expertise.
  • Bringing facilitation and collaboration work methods is our value add for the RegMed community.
  • Our grant search and feasibility capacity could also stimulate the future RegMed projects
  • We would definitely benefit from participating in the first life sciences ecosystem economy in our region.

Contact: avanechelpoel@cmast.be

De Clercq & Partners

RegMed platform

De Clercq & Partners is helping companies optimize the protection of their intellectual property in the field of regenerative medicine. Added value for the platform: Keeping track of legal developments in this field and informing the platform, identifying potential IP issues for initiatives of the platform.

GST

RegMed platform

GLOBAL STEM CELL TECHNOLOGY (GST) is a privately-owned company that is part of the Evergem based Health Care provider, ANACURA. GST focusses on the isolation and characterization of blood-derived mesenchymal stem cells and skin-derived epithelial stem cells. GST developed different organ culture systems and experimental animal models to properly assess these cells in vitro and in vivo.

Contact: jan.spaas@anacura.com

Layerwise (member of RegMed)

RegMed platform

3D Systems LayerWise makes its in-house developed metal 3D printing technology available for the manufacturing of complex metal parts and implants. These implants can feature complex designs and porous architectures that are optimized to achieve the desired tissue response in a regenerative medicine application and thus create ‘smart’ implants. Through the 3D Systems network, LayerWise also has access to 3D printing of biocompatible polymers.

Contact: Tim.VanCleynenbreugel@3DSystems.com

MaSTherCell

RegMed platform

MaSTherCell is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. The company operates a validated state-of-the-art cGMP facility in Gosselies.

thibault.jonckheere@masthercell.com

Medanex

Medanex Clinic is a CRO specialized in in preclinical in-vivo research using large animals (rabbit, sheep, goat, (mini)pig, cattle, llama and horse). Our main activities are pre-clinical studies and surgery trainings for academic research groups, medical device, pharmaceutical and biotech companies.

Our in-house equipment consists of state-of-the-art operating theatres, intensive care units, anesthetic equipment, fluoroscopy, ultrasonography and X-ray. We also provide MRI, CT and (histo)pathology services through experienced partners. Medanex’ core values are animal welfare, quality, flexibility and competence.

Contact: hadewych.vanhauwermeiren@medanex.com

Kennisinstellingen:

Division M3-BIORES (member of RegMed)

RegMed platform

The division M3-BIORES of the Department of Biosystems focuses on the development of model-based methods for monitoring and controlling of complex biological processes at different scales. M3-BIORES is partner of Prometheus and within the field of regenerative medicine the division aims at developing real-time process monitoring and controlling tools for optimizing in vitro cell cultures.

Contact: jean-marie.aerts@biw.kuleuven

IMEC (member of RegMed)

RegMed platform

Imec is a non-profit research organization in nanotechnology. At imec we aim to develop technology blocks for life sciences applications. As a member of the Regenerative Medicine innovation platform imec hopes to receive input from companies and research labs on the technology needs for novel bioreactors. We offer development on demand with input from stem cell researchers. Imec has a bilateral collaboration with Prometheus (KULeuven) to develop technology for controlled cell growth, focusing on lens-free imaging and biosensing.

Contact: Veerle.Reumers@imec.be  or  Peter.Peumans@imec.be

Prometheus

RegMed platform

Prometheus is a translational platform in the field of regenerative medicine. To achieve this, it integrates and advances the scientific and technological knowledge of its partners. This unique transdisciplinary team organizes its activities on the scientific, industrial-technical and preclinical level to develop robust and clinically relevant tissue engineering approaches for skeletal applications.

Contact: Frank Luyten, Frank.Luyten@uz.kuleuven.ac.be

Overheden en organisaties:

Leuven.Inc (member of Regmed)

RegMed platform

Our mission is to be a communication and facilitating platform, bringing together students, researchers, young starters, high-tech entrepreneurs, spin-offs and established enterprises and socio-economic partners. We do this through the coordination of events and activities, such as the (international) visionary seminars where an insight is given in the expected trends of the near future. In addition we organise numerous seminars on a specific technology or management theme, based on the present-day evolutions of the international technology market.

The Leuven.Inc  network covers areas of expertise ranging from micro and nano electronics, engineering, health and medical research to ICT, life sciences, food, materials and many more.

Contact: nicole.desmyter@leuveninc.com

New members are welcome to the platform

Up till now more than 40 members have joined the multidisciplinary platform. Regional governments, university labs, pharmaceutical companies (spin offs, SME or larger), hospitals, 3D-printing specialists, all sort of suppliers... venture capitalists and legal advisors are active participants. Crossborder cooperation with Nederlands Limburg has been established and the closing of the regional value chain is advancing.

Please contact: Jan Schrooten, jan.schrooten@antleron.com, tel +32 (0) 494 91 47 74

Members, please give us your short information for the memberpage

Our new memberpage is lacking lots of information . Please give us your company name, logo, url, short company role in regenerative medicine and added value to the platform, relevant images and contact info

    Een initiatief van:
  • {title}
  • {title}
  • {title}
  • {title}